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Lyme disease, the most commonly reported vector-borne disease in the United States, results from 
infection with Borrelia burgdorferi. Early clinical diagnosis of this disease is largely based on the 
presence of an erythematous skin lesion for individuals in high-risk regions. This, however, can be 
confused with other illnesses including southern tick-associated rash illness (STARI), an illness 
that lacks a defined etiological agent or laboratory diagnostic test, and is co-prevalent with Lyme 
disease in portions of the Eastern United States. By applying an unbiased metabolomics approach 
with sera retrospectively obtained from well-characterized patients we defined biochemical and 
diagnostic differences between early Lyme disease and STARI. Specifically, a metabolic 
biosignature consisting of 261 molecular features (MFs) revealed that altered N-acyl ethanolamine 
and primary fatty acid amide metabolism discriminated early Lyme disease from STARI. More 
importantly, development of classification models with the 261 MF biosignature and testing 
against validation samples differentiated early Lyme disease from STARI with an accuracy of 85 
to 98%. These findings revealed metabolic dissimilarity between early Lyme disease and STARI, 
and provide a powerful and new approach to objectively distinguish early Lyme disease from an 
illness with nearly identical symptoms.
Introduction
Lyme disease is a multisystem bacterial infection that in the United States is primarily 
caused by infection with Borrelia burgdorferi sensu stricto. Over 300,000 cases of Lyme 
disease are estimated to occur annually in the United States, with over 3.4 million laboratory 
diagnostic tests performed each year (1, 2). Symptoms associated with this infection include 
fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes; however, 
the most prominent clinical manifestation in the early stage is the presence of one or more 
erythema migrans (EM) skin lesions (3). This annular, expanding erythematous skin lesion 
occurs at the site of the tick bite in 70 to 80% of infected individuals and is typically 5 cm or 
more in diameter (4, 5). Although an EM lesion is a hallmark for Lyme disease, other types 
of skin lesions can be confused with EM (3, 5, 6). These include rashes caused by tick-bite 
hypersensitivity reactions, certain cutaneous fungal infections, bacterial cellulitis and the 
rash of southern tick-associated rash illness (STARI) (7, 8).
STARI, is associated with a bite from the lone star tick (Amblyomma americanum), and in 
addition to the development of an EM-like skin lesion, individuals with STARI can present 
with mild systemic symptoms (including muscle and joint pains, fatigue, fever, chills, and 
headache) that are similar to those occurring in patients with Lyme disease (7, 9, 10). These 
characteristics of STARI have led some to postulate that the etiology of this illness is a 
Borrelia species, including B. burgdorferi (10, 11) or B. lonestari (12–15); however, multiple 
studies have refuted that STARI is caused by B. burgdorferi (7, 16–19) and additional cases 
associating B. lonestari with STARI have not emerged (20, 21). Additionally, STARI 
patients have been screened serologically for reactivity to rickettsial agents, but no evidence 
was obtained to demonstrate that rickettsia causes this illness (10, 22). Thus, at present no 
infectious etiology is known for STARI.
STARI cases occur over the geographic region where the lone star tick is present. This 
includes a region that currently expands from central Texas and Oklahoma upward into the 
Molins et al. Page 2
Sci Transl Med. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Midwestern states and eastward, including the southern states and along the Atlantic coast 
into Maine (23). Unlike STARI, Lyme disease is transmitted to humans through the bite of 
the blacklegged tick (Ixodes scapularis) that is present in the northeastern, mid-Atlantic, and 
north-central United States, and the western blacklegged tick (I. pacificus), which is present 
on the Pacific Coast (24). The geographic distribution of human Lyme disease and the 
vectors for this disease is expanding (24–26), and there is a similar expansion of areas 
inhabited by the lone star tick (23). Importantly, a strict geographic segregation of Lyme 
disease and STARI does not exist, as there are regions where STARI and Lyme disease are 
co-prevalent (25). Thus, there is a growing need for diagnostic methods to differentiate 
between Lyme disease and STARI, and that facilitate proper treatment, patient management 
and disease surveillance.
Clinically, the skin lesions of STARI and early Lyme disease are indistinguishable, and no 
laboratory tool or method exists for the diagnosis of STARI or differentiation of STARI from 
Lyme disease. The only biomarkers evaluated for differential diagnosis of early Lyme 
disease and STARI have been serum antibodies to B. burgdorferi (10, 16). However, these 
tests have poor sensitivity for early stages of Lyme disease, and thus a lack of B. burgdorferi 
antibodies cannot be used as a reliable differential marker for STARI. We previously 
demonstrated that metabolic profiling of sera provided a high level of accuracy in 
differentiating early Lyme disease patients from healthy individuals and those with diseases 
or conditions that are confounders for existing serological-based laboratory tests of Lyme 
disease (27). Thus, we now postulate that a metabolomics-driven approach will identify 
biomarkers that discriminate early Lyme disease from STARI, and provide evidence that 
these two diseases are biochemically distinct. A retrospective cohort of well-characterized 
sera from patients with early Lyme disease and STARI was evaluated to identify a 
differentiating metabolic biosignature. Using statistical modeling, this metabolic 
biosignature accurately classified test samples that included healthy controls. Additionally, 
the metabolic biosignature revealed that N-acyl ethanolamine (NAE) and primary fatty acid 
amide (PFAM) metabolism differed significantly between these two diseases.
Results
Clinical samples
A total of 220 well-characterized retrospective serum samples from three different 
repositories were used to develop and test a metabolic biosignature that accurately classifies 
early Lyme disease and STARI (table S1). All samples from Lyme disease patients were 
culture confirmed and/or PCR positive for B. burgdorferi. The median age for early Lyme 
disease patients was 45 years and 74% were males. STARI patients had an overall median 
age of 45 years and 55% were males.
To establish a Lyme disease diagnostic baseline, the recommended two-tiered serology 
testing for Lyme disease was performed on all samples. First-tier testing was performed 
using the C6 EIA and was positive for 66% of Lyme disease samples. When STARI and 
healthy controls were tested by the C6 EIA, two STARI samples (2%) and five healthy 
controls (9%) tested positive or equivocal. Two-tiered testing using IgM and IgG 
immunoblots as the second-tier test following a positive or equivocal first-tier assay resulted 
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in a sensitivity of 44% for early Lyme disease samples (duration of illness was not 
considered for IgM immunoblot testing). The sensitivity of two-tiered testing for early Lyme 
disease samples included in the Discovery/Training-Sets and the Test-Sets was 40% and 
50%, respectively. All STARI and healthy control samples were negative by two-tiered 
testing (table S1).
Development of a metabolic biosignature for early Lyme disease and STARI differentiation
Metabolic profiling by liquid chromatography-mass spectrometry (LC-MS) of a 
retrospective cohort of well-characterized sera from patients with early Lyme disease (n=40) 
and STARI (n=36) (table S1 and Fig. 1A) comprising the Discovery-Set (i.e. Test-Set 
samples were not used in molecular feature selection) resulted in a biosignature of 792 
molecular features (MFs) that differed significantly (adjusted-p<0.05) with a ≥ 2 fold change 
in relative abundance between early Lyme disease and STARI. Down-selection of MFs 
based on their robustness in replicate analyses of the same sera produced a refined 
biosignature of 261 MFs (Fig. 1A and table S2). Of these 261 MFs, 60 and 201 displayed an 
increased and decreased abundance, respectively, in early Lyme disease as compared to 
STARI. The large number of MFs that differed significantly between early Lyme disease and 
STARI patients indicated that these two patient groups had distinguishing biochemical 
profiles. These variances could be applied to define alterations of specific metabolic 
pathways (Fig. 1A) and used to develop diagnostic classification models (Fig. 1B).
In silico analysis of metabolic pathways
Presumptive chemical identification was applied to the 261 MFs. This yielded predicted 
chemical formulas for 149 MFs and 122 MFs were assigned a putative chemical structure 
based on interrogation of each MF’s monoisotopic mass (+ or − 15 ppm) against the Metlin 
database and the Human Metabolome Database (HMDB) (table S2). An in silico 
interrogation of potentially altered metabolic pathways was performed using the 
presumptive identifications for the 122 MFs and MetaboAnalyst (28). Four differentiating 
pathways were predicted to have the greatest impact, with glycerophospholipid and 
sphingolipid metabolism having the most number of assigned metabolites (Fig. 2 and table 
S3). Specifically, the MetaboAnalyst analysis indicated that differences in phosphatidic acid, 
phosphatidylethanolamine, phosphatidylcholine and lysophosphotidylcholine were the major 
contributors to altered glycerophospholipid metabolism between STARI and early Lyme 
disease (table S3). Altered sphingolipid metabolism between these two groups was 
attributable to changes in the relative abundances of sphingosine, dehydrosphinganine and 
sulfatide (table S3). Manual interrogation of the predicted structural identifications revealed 
that 26 and 7 of the 122 MFs assigned a putative structural identification were associated 
with glycerophospholipid and sphingolipid metabolism, respectively (table S2).
Elucidation of altered NAE metabolism
The prediction of altered metabolic pathways was based on the presumptive structural 
identification of the early Lyme disease versus STARI differentiating MFs. Thus, to further 
define the metabolic differences between these two patient groups, structural confirmation of 
selected MFs was undertaken. Two MFs that displayed relatively large abundance 
differences (m/z 300.2892, RT 19.66; and m/z 328.3204, RT 20.72) were putatively 
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identified as sphingosine-C18 or 3-ketosphinganine, and sphingosine-C20 or N,N-dimethyl 
sphingosine, respectively. However, both of these MFs had alternative predicted structures of 
palmitoyl ethanolamide and stearoyl ethanolamide, respectively. The interrogation of 
authentic standards against these two serum MFs revealed RTs and MS/MS spectra that 
identified the m/z 300.2892 and m/z 328.3204 products as palmitoyl ethanolamide (Fig. 3A 
and 3B) and stearoyl ethanolamide (fig. S1), respectively. These two products, as well as 
other NAEs, are derived from phosphatidylethanolamine and phosphatidylcholine, and 
represent a class of structures termed endocannabinoids and endocannabinoid-like (29) (Fig 
3C). Further analysis of the 122 MFs identified five additional MFs with a predicted 
structure that mapped to the NAE pathway. Specifically, MF m/z 286.2737, RT 19.08 was 
putatively identified as a sphingosine-C17 or pentadecanoyl ethanolamide, and was 
confirmed to be the latter (fig. S2). MF m/z 356.3517, RT 21.67 was putatively identified 
and confirmed to be eicosanoyl ethanolamide (fig. S3), and MF m/z 454.2923, RT 18.08 was 
confirmed to be glycerophospho-N-palmitoyl ethanolamine (fig. S4), an intermediate in the 
formation of palmitoyl ethanolamide. A second group of lipids, the PFAMs that act as 
signaling molecules and that are potentially associated with the metabolism of NAEs were 
also identified as having significant relative abundance differences between the early Lyme 
disease and STARI patient samples. Specifically, MFs m/z 256.2632, RT 20.08; m/z 
284.2943, RT 21.15; and m/z 338.3430, RT 22.14 were confirmed to be palmitamide (Fig. 
3D and 3E), stearamide (fig. S5) and erucamide (fig. S6), respectively.
The large number of differentiating MFs associated with NAE metabolism suggested that 
this is a major biological difference between STARI and early Lyme disease (Fig. 3C and 
table S2). Four additional MFs of the 261 MF biosignature, and that fit known host 
biochemical pathways were also structurally confirmed. These included L-phenylalanine 
(fig. S7), nonanedioic acid (fig. S8), glycocholic acid (fig. S9) and 3-carboxy-4-methyl-5-
propyl-2-furanpropanoic acid (CMPF) (fig. S10). Additionally, two MFs that provided 
strong matches to MS/MS spectra in the Metlin databases were putatively identified as 
arachidonoyl lysophosphatidic acid [Lyso PA (20:4)] (fig. S11) and 3-ketosphingosine (fig. 
S12).
The 261 MF biosignature list revealed metabolic dissimilarity between Lyme disease and 
STARI
We hypothesized that early Lyme disease and STARI represent distinct metabolic states that 
would be reflected in a comparison of MFs’ relative abundances in these two disease states 
to those of healthy controls. The majority of MFs in early Lyme disease and STARI sera 
maintained fold change differences with respect to healthy controls. This provided evidence 
for metabolic separation of early Lyme disease and STARI patient samples (Fig. 4A). For 
three MFs (3-ketosphingosine, CMPF, and Lyso PA 20:4), the levels in early Lyme disease 
were increased as compared to the healthy controls while the levels in STARI were 
decreased. Additionally, all of the NAEs and PFAMs had relative abundances in early Lyme 
disease patients that were closer to those of healthy controls, whereas the relative 
abundances in STARI were greatly increased. This analysis was expanded to all 261 MFs of 
the early Lyme disease-STARI biosignature. The total number of MFs with increased and 
decreased abundances relative to healthy controls was similar for both early Lyme disease 
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and STARI within the different abundance fold change ranges (Fig. 4B). However, when 
individual MFs with increased or decreased abundances relative to healthy controls were 
compared between early Lyme disease and STARI a strong difference emerged, with only 0 
to 30% of MFs shared between early Lyme disease and STARI yielding the same directional 
and similar abundance fold change (Fig. 4C). This indicated that the metabolic changes in 
early Lyme disease and STARI as compared to healthy controls differed.
Diagnostic classification of early Lyme disease vs STARI
Classification models were used to determine whether the 261 MF biosignature could be 
applied to discriminate early Lyme disease from STARI (Table 1 and Fig. 1B). Specifically, 
two classification models, least absolute shrinkage and selection operator (LASSO) and 
random forest (RF) were trained with the 261 MF biosignature using abundance data from 
the Training-Set samples only (Fig. 1B). Test-Set samples were not used for molecular 
feature selection or to train the classification models. The LASSO model selected 38 MFs, 
and RF by default does not perform feature selection and thus used all 261 MFs for 
classification of the STARI and early Lyme disease patient populations (table S2). Note, 
table S4 provides the regression coefficients for the 38 MFs selected by LASSO. When Test-
Set samples (Fig. 1B) (i.e. those not included in the Discovery/Training-Set) were tested in 
duplicate, early Lyme disease samples were classified by RF and LASSO with an accuracy 
of 97% and 98%, respectively. The STARI samples had a classification accuracy of 89% 
with both models (Table 1 and table S5). A depiction of the LASSO scores for the Test-Set 
data showed segregation of the early Lyme disease and STARI patient samples, and 
demonstrated the discriminating power of the 38 MFs selected by the LASSO model (Fig. 
5A). A receiver operating characteristic (ROC) curve was plotted to demonstrate the 
performance of the LASSO model for differentiating early Lyme disease from STARI 
patients. The area under the curve (AUC) was calculated to be 0.986 (Fig. 5B). The 38 MFs 
of the LASSO model encompassed four of the 14 structurally confirmed metabolites: CMPF, 
L-phenylalanine, palmitoyl ethanolamide, and arachidonoyl lysophosphatidic acid (table 
S2).
Diagnostic classification of early Lyme disease vs STARI vs healthy controls
Separate three-way classification models using LASSO and RF were developed by including 
LC-MS data collected for healthy controls in the Training-Set samples (Fig. 1B). For model 
training LASSO selected 82 MFs (table S2). The regression coefficients for the 82 MFs 
selected by LASSO are provided in table S6. Evaluation of the RF and LASSO three-way 
classification models with Test-Set samples (those not used in the Discovery/Training-Sets) 
reveled classification accuracies of 85% and 92% for early Lyme disease and STARI, 
respectively. Surprisingly, healthy controls were classified with accuracies of 95% and 93% 
with the RF and LASSO models, respectively (Table 1 and table S7). Plotting of LASSO 
scores calculated for Test-Set data revealed three groupings that corresponded with early 
Lyme disease, STARI and healthy controls (Fig. 5C). Of the early Lyme disease samples that 
were misclassified with the RF model (n=9), all were predicted to be healthy controls; and 
those misclassified by the LASSO model (n=9), three were classified as STARI and six as 
healthy controls. Of the STARI samples that were misclassified by the RF and LASSO 
models (n=3 for both models), all samples were misclassified as early Lyme disease. When 
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healthy controls were misclassified using the RF model (n=2) and LASSO model (n=3), all 
were misclassified as early Lyme disease.
Of the 38 MFs selected by LASSO for the two-way classification model, 33 were included 
in the 82 MFs of the LASSO three-way classification model (table S2). The 82 MFs of the 
LASSO three-way classification included seven of the 14 structurally confirmed metabolites: 
3-ketosphingosine, glycocholic acid and pentadecanoyl ethanolamide, as well as the four 
included in the LASSO two-way classification model (table S2).
Biosignature was not influenced by geographic variability
Since retrospective samples collected by multiple laboratories were used in these studies, we 
assessed whether a geographic bias was introduced. Pair-wise comparisons, by sample 
source, of mean LASSO scores and mean RF probabilities of STARI and healthy control 
Test-Set data were performed with ANOVA followed by computation of simultaneous 
confidence intervals using Tukey’s method (table S8 and S9). These results demonstrated 
that all STARI samples grouped together regardless of source, and differ from healthy 
controls. Likewise, the healthy controls from Colorado and New York were considered a 
single group that differed from STARI based on the LASSO healthy control or STARI 
scores, and the RF classification probabilities for healthy controls. The only outlier noted in 
theses analyses was the New York healthy controls, but this was only when the ANOVA was 
performed with RF classification probabilities for STARI.
The grouping of the samples based on disease state and not geographic distribution was also 
evaluated by linear discriminant analysis using the 82 MFs of the LASSO three-way 
classification model (Fig. 6). For this analysis healthy controls from Florida, a region with 
low prevalence for Lyme disease and reported to have STARI cases, were included to 
evaluate whether samples collected in the southern United States would differ from those 
collected in New York or Colorado. For STARI, three patient samples groups collected in 
Missouri, NC and other states (included VA, GA, KY, TN, AL, IA and NE) were compared. 
The linear discriminant analysis demonstrated that although slight variation exists between 
the three healthy control groups (NY, CO and FL), there is greater variability between all 
healthy controls and all STARI samples than within healthy controls or STARI samples 
based on geographic location of collection (Fig. 6).
Discussion
The inability to detect B. burgdorferi by PCR or culture, no serological response to B. 
burgdorferi antigens in STARI patients, and transmission by different tick species are 
accepted as evidence that the etiologies of STARI and Lyme disease differ (7–8,16, 25). 
Nevertheless, an overlap in clinical symptoms, including the development of an EM-like 
skin lesion, creates confusion and controversy for the clinical differentiation of STARI and 
Lyme disease (30). The data reported here demonstrated marked differences between the 
metabolic profiles of early Lyme disease and STARI patients, and thus provide compelling 
positive data to support the concept that these two illnesses are distinct entities. Metabolic 
pathway analyses and the structural identification of several MFs with significant abundance 
differences between early Lyme disease and STARI identified multiple NAEs. These 
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endogenous lipid mediators are derived from phosphatidylcholine and 
phospahtidylethanolamine via the endocannabinoid system (Fig. 3C) (29). 
Arachidonoylethanolamide (AEA), a widely studied endocannabinoid, is an endogenous 
agonist of the cannabinoid receptors; however, it is a minor component of animal tissues. In 
contrast, congeners of AEA, such as the NAEs identified in the early Lyme disease-STARI 
biosignature, are significant products of animal tissues, including the skin (29, 31). The 
serum levels of NAEs possessing long-chain saturated fatty acids were significantly 
increased in the serum of STARI patients. These are produced in response to inflammation, 
and act in an anti-inflammatory manner as agonists of PPAR-α or by enhancing AEA 
activity (32, 33). The NAEs can be converted to N-acylglycine structures via an alcohol 
dehydrogenase, and further degraded to PFAMs (34). Interestingly, our data not only 
demonstrated a STARI-associated increase in NAEs with saturated fatty acids, but also an 
increase in the corresponding PFAMs. Although the mechanism for the increased NAE and 
PFAM levels in STARI patients is unknown, decreased fatty acid amide hydrolase activity 
that liberates fatty acids from both NAEs and PFAMs (35) would result in the observed 
increase in abundance of these metabolites. The anti-inflammatory activity of the NAEs also 
raises the possibility that these metabolites are partially responsible for the milder symptoms 
associated with STARI (9). As the enzymes involved with the genesis and degradation of 
NAEs and PFAMs are known (29, 36), studies can be constructed to further elucidate the 
mechanism(s) by which NAEs and PFAMs accumulate in the sera of STARI patients.
We previously demonstrated proof-of-concept for a discriminating metabolic biosignature of 
early Lyme disease (27). This current work expands on the utility of this approach by 
demonstrating the ability to distinguish early Lyme disease from an illness with nearly 
identical symptoms or what would be considered a Lyme disease-like illness (37). The 
existing diagnostic algorithm for Lyme disease is a two-tiered serologic approach that 
utilizes an EIA or IFA as a first-tier test followed by IgM and IgG immunoblotting as the 
second-tier test (38). For early Lyme disease, the sensitivity of this diagnostic is 29–40% and 
the specificity is 95–100% (39). The current antibody-based approaches do not distinguish 
between active and previous infections, an important limitation. In the current study all of 
the STARI samples were negative by two-tiered testing, and only 2% were positive by the 
first-tier EIA. Early Lyme disease samples were 44% positive (40% positivity for the early 
Lyme disease samples used in the Discovery and Training Sets and 50% positivity for early 
Lyme disease samples used in the Test Sets) by two-tiered testing. In contrast, when 
classification modeling was applied to the 261 MFs of the early Lyme disease-STARI 
biosignature, diagnostic accuracy for early Lyme disease was dramatically increased (85 to 
98% accuracy depending on the model) as compared to serology. Classification by RF or 
LASSO was overall highly accurate for early Lyme disease and STARI, in particular when 
using the two-way classification models. Interestingly, when healthy controls were 
introduced and used to develop a three-way classification model there was a slight increase 
in the accuracy for STARI and decrease in the accuracy for early Lyme disease, but healthy 
controls were classified with a 93–95% accuracy. This was surprising as healthy controls 
were not used to create the initial 261 MF biosignature, and furthers supported that STARI 
and early Lyme disease are metabolically distinct from healthy controls, but in different 
ways.
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To date the development of a diagnostic tool for STARI or for differentiation of early Lyme 
disease and STARI has received little attention. As the geographic distribution of Lyme 
disease continues to expand (25, 26), so will the geographic range where there is overlap of 
Lyme disease and STARI. Thus, a diagnostic tool that accurately differentiates these two 
diseases could have a major impact on patient management. Lyme disease is treated with 
antibiotics, and although there is no defined infectious etiology for STARI, this illness is 
also commonly treated in a similar manner (7, 20, 40). Establishment of a robust diagnostic 
tool would not only facilitate antibiotic stewardship, it would also allow for proper studies to 
assess the true impact of therapies for STARI. Lyme disease is also a reportable disease and 
in order to maintain accurate disease surveillance in low incidence areas, it is essential that 
diseases such as STARI be excluded (30). Additionally, vaccines are currently being 
developed for Lyme disease (41–44) and as these are tested, it will be important to identify 
STARI patients in order to properly assess vaccine efficacy.
To apply the discoveries of this work towards the development of an assay that can be used 
for the clinical differentiation of early Lyme disease and STARI, it must first be determined 
whether an emphasis should be placed on the diagnosis of Lyme disease or STARI. As there 
is no defined etiology of STARI, and Lyme disease is not necessarily self-limiting without 
antibiotics and can have subsequent complications if untreated, we envision that the final 
assay would focus on being highly sensitive for early Lyme disease and be primarily applied 
in regions where Lyme disease and STARI overlap. Although existing laboratory tests for 
Lyme disease emphasize specificity, this strategy needs to be reconsidered for a differential 
diagnostic test of STARI and early Lyme disease, since any illness presenting with an EM in 
a region with a known incidence of Lyme disease would likely be treated with antibiotics (7, 
20, 40). As with all diagnostic tests, use of a metabolic biosignature for differentiation of 
early Lyme disease and STARI would need to be performed in conjunction with clinical 
evaluation of the patient, and consideration of their medical history and epidemiologic risk 
for these two diseases.
The approach outlined in this study applies semi-quantitative mass spectrometry and the use 
of biochemical signatures for the classification of patients. Clinical application of such an 
approach would likely occur in a specialized clinical diagnostic laboratory. At this point it is 
difficult to accurately assess the cost benefits of a MS based assay; however, it should be 
noted that the second-tier immunoblot assays for the serological diagnosis of Lyme disease 
are already performed in specialized laboratories (1, 45, 46). Further a LC-MS assay for a 
single sample performed as described in this work takes about 1.5 h from sample processing 
to data collection. MS assays are currently used in clinical laboratories for the analyses of 
small molecule metabolites. The majority of these tests are under Clinical Laboratory 
Improvement Amendments (CLIA) guidelines, but an FDA cleared mass spectrometry-based 
test for inborn metabolic errors is in use (47). The most accurate quantification of 
metabolites by mass spectrometry is achieved by Multiple Reaction Monitoring (MRM) 
assays (48). Such assays are developed with the knowledge of a MF’s chemical structure. To 
this end, we have identified the chemical structure of 14 MFs and are continuing to identify 
those that have the greatest fold change difference and reproducibility. It should be noted 
that the NAEs and PFAMs that were revealed via our pathway analyses are amenable to 
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MRM assays (49). These metabolites are now being investigated for their ability to 
accurately classify STARI and early Lyme disease.
The data reported here were generated from the analysis of retrospectively collected serum 
samples from various repositories that have been archived for different lengths of time. To 
reduce the impact of the potential variability associated with these samples, stringent criteria 
were applied to the data analysis. In addition to the requirement of a significant fold change, 
those MFs selected for the final early Lyme disease-STARI biosignature were required to be 
present in at least 80% of samples within a sample group and maintain the median fold-
change difference in at least 50% of samples within a group. While the STARI and healthy 
control sera were collected by multiple laboratories and from multiple geographic locations, 
the early Lyme disease sera was obtained from a single laboratory. This is a potential 
limitation of the study. However, linear discriminate analysis was applied to assess the 
variability within the healthy control and STARI samples collected by different laboratories. 
This analysis demonstrated little to no variability among the STARI or healthy control 
samples indicating that the criteria used for MF selection effectively reduced non-biological 
variability. As we have noted, data were collected by non-absolute semi-quantitative mass 
spectrometry. Nevertheless, this is a common practice applied in the development of 
differentiating biosignatures for infectious diseases (27, 50–53), and our workflow ensured 
that the most robust MFs were selected and used for classification modeling. This included 
the use of full technical replicates that controlled for potential variability introduced during 
sample processing and LC-MS analyses. Although the use of replicate samples could have 
biased the discriminating power of the classification models for the Training-Set data, the 
use of an independent hold out Test-Set prevents this from being a problem for model 
testing.
Without knowledge of a known etiologic agent, we recognize that STARI simply 
encompasses a clinical syndrome. The STARI samples used in this current work included 
those collected in studies used to define this illness (9), as well as samples collected outside 
those original studies. Ongoing efforts are directed at prospective collection of additional 
samples that will be useful to assess the applicability of our current metabolic biosignature 
in a real-world scenario. Future sample collection will also target patient populations with 
non-Lyme EM-like lesions, including tick-bite hypersensitivity reactions, certain cutaneous 
fungal infections and bacterial cellulitis. Additionally, other factors such as confections with 
other vector-borne pathogens will need to be addressed with prospective studies. In the 
Southeastern United States, there is evidence for enzootic transmission of B. burgdorferi; 
however, it is debatable whether Lyme disease occurs in this region (11, 30, 54, 55). The 
current study was not designed to provide evidence for or against the presence of Lyme 
disease in the southern United States. Nevertheless, metabolic profiling offers a novel 
approach that is orthogonal to the methods currently employed to address this issue.
Materials and Methods
Study design
STARI is an illness that has received little attention over the years, but is a confounding 
factor in diagnosing early Lyme disease in areas where both illnesses overlap and contributes 
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to the debate surrounding the presence of Lyme disease in the southern United States. No 
diagnostic tool exists for STARI or for differentiating early Lyme disease from STARI. 
Based on documented differences between early Lyme disease and STARI (9, 16, 56), we 
hypothesized that metabolic profiling of serum would permit development of a biochemical 
biosignature that when applied could accurately classify early Lyme disease and STARI 
patients. For this reason, we designed an unbiased-metabolomics study to directly compare 
the metabolic host responses between these two illnesses, and subsequently evaluate how 
this metabolic biosignature distinguishes these two illnesses. The use of unbiased 
metabolomics for biosignature discovery does not lend itself to power calculations to 
determine sample size. Thus, sample sizes were selected based on our previous studies (27, 
50, 51). To obtain a sufficient number of well-characterized STARI sera, retrospectively 
collected samples from two separate studies were used. Specifically, the first set of STARI 
serum samples (n=33) was obtained from the CDC repository. These samples were collected 
through a prospective study performed between 2007 and 2009 (57). Patients were enrolled 
through CDC outreach efforts (n=17) or by contract with the University of North Carolina at 
Chapel Hill (n=16). The states where patients were recruited included NC, 18; VA, 4; TN, 3; 
KY, 2; GA, 2; IA, 2; AL, 1; and NE, 1. All samples were collected pre-treatment with the 
exception of one patient who was treated with doxycycline 1–2 days before the serum 
sample was obtained. The second set of STARI samples (n=22) was obtained from the New 
York Medical College serum repository (20). These samples were collected between 2001 
and 2004 from patients living in Missouri.
Sufficient numbers of well-characterized early Lyme disease serum samples were acquired 
from New York, an area of high incidence for Lyme disease and low incidence of STARI (9). 
Specifically, all early Lyme disease samples (n=70) were culture and/or PCR positive for B. 
burgdorferi and were collected pre-treatment. To ensure appropriate representation of both 
non-disseminated and disseminated forms of early EM Lyme disease, samples from patients 
with a single EM that were skin culture and/or PCR positive for B. burgdorferi and blood 
culture negative (n=35), and patients with multiple EMs or a single EM that were blood 
culture positive (n=35) were used. Early Lyme disease samples were collected between 1992 
and 2007, and 1 to 33 days post-onset of symptoms. To understand the relationship of our 
findings to a healthy control population serum samples from healthy donors were also 
included in the study. These were procured from repositories at New York Medical College, 
the CDC and the University of Central Florida. A detailed description of inclusion and 
exclusion criteria for each patient and donor population is provided in table S1. All 
participating institutions obtained institutional review board (IRB) approval for this study. 
IRB review and approval for this study ensured that the retrospective samples used had been 
collected under informed consent.
All samples were analyzed in duplicate and were randomized prior to processing for LC-MS 
analyses. Healthy control sera were used as quality control samples for each LC-MS 
experiment. The serum samples and respective LC-MS data files of each patient group and 
healthy controls were randomly separated into a Discovery-Set,/Training-Sets 1 and 2, and 
Test-Sets 1 and 2. Specifically, 40 of the 70 early Lyme disease and 36 of the 55 STARI 
samples were randomly selected as the Discovery-Set samples. This sample set was used for 
molecular feature selection. To train the classification models, two training-sets were used. 
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The first, Training-Set 1, was identical to the Discovery-Set (i.e. contained the same early 
Lyme disease and STARI samples) and the second, Training-Set 2, consisted of the same 
samples as Training-Set 1 with the addition of 38 of the 58 healthy control samples. Lastly, 
Test-Sets 1 and 2 were created. Test-Set 1 was comprised of 30 early Lyme disease and 19 
STARI samples that were not included in the Discovery/Training samples sets. Test-Set 2 
consisted of the same samples as those used in Test-Set 1 with the addition of 20 healthy 
control samples that were not included in the Training-Set 2 samples. Test-Sets 1 and 2 were 
exclusively used for blinded testing of the classification models.
Randomization into Discovery/Training-Sets or Test-Sets was done in a manner that ensured 
bias was not introduced based on the repository from which STARI samples were obtained 
or on whether the early Lyme disease samples were from a non-disseminated or 
disseminated case. Biosignature development was performed by screening MFs based on 
stringent criteria outlined in Fig. 1A and detailed in the Biosignature development section 
(below).
Lyme disease serologic testing of all serum samples
Standard two-tiered testing was performed on all samples (38). The C6 B. burgdorferi 
(Lyme) ELISA (Immunetics, Boston, MA) was used as a first-tier test, and any positive or 
equivocal samples were reflexed to Marblot IgM and IgG immunoblots (MarDx Diagnostics, 
Inc., Carlsbad, CA) as the second-tier test. Serologic assays were performed according to the 
manufacturer’s instructions, and the data were interpreted according to established CDC 
guidelines (38). Duration of illness, however, was not considered for test interpretation.
Liquid chromatography-mass spectrometry (LC-MS)
Serum samples were randomized prior to extraction of small molecule metabolites and LC-
MS analyses. Small molecule metabolites were extracted from sera as previously reported 
(27). An aliquot (10 µl) of the serum metabolite extract was applied to a Poroshell 120, EC-
C8, 2.1 × 100 mm, 2.7 µm LC Column (Agilent Technologies, Palo Alto, CA). The 
metabolites were eluted with a 2–98% nonlinear gradient of acetonitrile in 0.1% formic acid 
at a flow rate of 250 µl/min with an Agilent 1200 series LC system. The eluent was 
introduced directly into an Agilent 6520 quadrapole time of flight mass (Q-TOF) 
spectrometer and MS was performed as previously described (27, 50). LC-MS and LC-
MS/MS data were collected under the following parameters: gas temperature, 310°C; drying 
gas at 10 liters per min; nebulizer at 45 lb per in2; capillary voltage, 4,000 V; fragmentation 
energy, 120 V; skimmer, 65 V; and octapole RF setting, 750 V. The positive-ion MS data for 
the mass range of 75 to 1,700 Da were acquired at a rate of 2 scans per sec. Data were 
collected in both centroid and profile modes in 4-GHz high-resolution mode. Positive-ion 
reference masses of 121.050873 m/z and 922.009798 m/z were introduced to ensure mass 
accuracy. To monitor instrument performance, quality control samples consisting of a 
metabolite extract of healthy control serum (BioreclamationIVT, Westbury, NY) was 
analyzed in duplicate at the beginning of each analysis day and every 20 samples during the 
analysis day.
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Biosignature development
LC-MS data from an initial Discovery-Set of samples comprised of randomly selected early 
Lyme disease (n=40) and randomly selected STARI patients (n=36) that were exclusively 
used for molecular feature selection and classification model training were processed with 
the Molecular Feature Extractor algorithm tool of the Agilent MassHunter Qualitative 
Analysis software version B.05.00 (Agilent Technologies, Santa Clara, CA). The MFs were 
aligned between data files with a 0.25 min retention time window and 15 ppm mass 
tolerance. Comparative analyses of differentiating MFs between patient groups were 
performed using the workflow presented in Fig.1A. Specifically, the Discovery-Set data was 
analyzed using Mass Profiler Pro (MPP) software version B.12.05 (Agilent Technologies). 
Using MPP a univariate, unpaired t-test was performed on each metabolite to test for a 
difference in mean (standardized) abundance between early Lyme disease and STARI 
groups. Multiple testing was accounted for by computing false-discovery rate (FDR)-
adjusted p-values (Benjamin and Hochberg, 1995). To prevent selection of MFs biased by 
uncontrolled variables (diet, other undisclosed illnesses, etc.), only MFs present in 50% or 
more of samples in at least one group and that differed between the groups with a 
significance of adjusted-p<0.05 were selected. Quantitative Analysis software version B.
05.01 (Agilent Technologies) was used to extract area abundance values for all differentially 
selected MFs from the MS data files. Duplicate MFs were removed by assessing adduct 
ions, as well as mass, retention time and abundance similarities; this resulted in the 
Discovery MF List. A duplicate LC-MS analysis of the Discovery-Set samples was 
performed and the area abundance for MFs of the discovery MF List were extracted using 
the Quantitative Analysis software. These data with those from the first LC-MS analysis 
formed the Targeted-Discovery-Set.
Abundance data from the Targeted-Discovery-Set data files were normalized using a two-
step method. First, abundances (area under the peak for the monoisotopic mass) of each 
Discovery MF were normalized by the median intensity of the stable MFs detected in each 
individual sample (58). Stable MFs were those identified in the original extraction of LC-
MS data files with the Agilent MassHunter Qualitative Analysis software and present in at 
least 50% of all sample data files. Secondly, median fold changes of stable MFs between the 
initial quality control sample (applied at the beginning of the LC-MS analysis) and each of 
the subsequent quality control samples (applied every 20 clinical samples throughout the 
LC-MS analysis) were calculated. The median fold change calculated for the quality control 
sample that directly followed each series of 20 clinical samples was multiplied against the 
normalized Discovery-MF abundances in the clinical samples of that series. This second 
normalization step was performed to correct for instrument variability. To apply stringency 
to the development of a final early Lyme disease-STARI biosignature, MFs were filtered 
based on consistency in the duplicate LC-MS data sets by requiring the same directional 
abundance change between the patient groups. Specifically, MFs with at least a ≥ 2-fold 
abundance difference and a 1.5-fold abundance difference between the medians of the two 
groups (early Lyme disease and STARI) for LC-MS analysis-1 and LC-MS analysis-2, 
respectively, were selected. Further criteria applied to ensure that the most robust MFs were 
being selected included: removing MFs with > 20% missing values in both groups, and 
selecting only MFs where at least 50% of the samples within a patient group produced a fold 
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change of ≥ 2 in comparison to the mean of the other patient group. This selection process 
resulted in the MFs included in the early Lyme disease-STARI biosignature.
Prediction and verification of MF chemical structure
Confirmation of the chemical structures of selected MFs was performed by LC-MS-MS to 
provide level-1 or level-2 identifications (59). Commercial standards palmitoyl 
ethanolamide, stearoyl ethanolamide, eicosanoyl ethanolamide, glycerophospho-N-palmitoyl 
ethanolamine, pentadecanoyl ethanolamide, and erucamide were obtained from Cayman 
Chemical (Ann Arbor, MI, USA). Commercial standards piperine and nonanedioic acid 
were obtained from Sigma Aldrich (Saint Louis, MO, USA). Commercial standards methyl 
oleate, stearamide, palmitamide, CMPF, and glycocholic acid were obtained from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The LC conditions used were the same as 
those used for the LC-MS analyses of serum metabolites. MS/MS spectra of the targeted 
MFs and commercial standards were obtained with an Agilent 6520 Q-TOF mass 
spectrometer. Electrospray ionization was performed in the positive ion mode as described 
for MS analyses, except the mass spectrometer was operated in the 2 GHz extended dynamic 
range mode. The positive ion MS/MS data (50 to 1,700 Da) were acquired at a rate of 1 scan 
per sec. Precursor ions were selected by the quadrupole and fragmented via collision-
induced dissociation (CID) with nitrogen at collision energies of 10, 20, or 40 eV. To provide 
a level-1 identification, the MS/MS spectra of the targeted metabolites were compared to 
spectra of commercial standards. Additionally, LC retention time comparisons between the 
targeted MF and the respective standard were made. A retention time window of ± 5 sec was 
applied as a cutoff for identification. The MS/MS spectra of selected serum metabolites were 
compared to spectra in the Metlin database for a level-2 identification.
Metabolic pathway analysis by MetaboAnalyst
The experimentally obtained monoisotopic masses corresponding to the MFs of the 261 
biosignature list were searched against HMDB using a 15 ppm window. The resulting list of 
potential metabolite structures were applied to the MetaboAnalyst pathway analysis tool 
(28) Settings for pathway analysis consisted of applying Homo sapiens pathway library; the 
Hypergeometric Test for the over-representation analysis and Relative-betweenness 
centrality to estimate node importance in the pathway topology.
Statistical analyses
Methods to filter the list of MFs and to normalize abundances are described in the section on 
biosignature development. Prior to analysis, the normalized abundances were log2 
transformed and each MF was scaled to have a mean of zero and standard deviation of 1. 
Statistical analyses were performed using R software (60).
Classification Modeling—For classification modeling, Training- and Test-Set samples 
were used as previously described (27, 50) and as shown in Fig. 1B. Separate classification 
analyses were performed for comparison of two groups (early Lyme disease and STARI) and 
three groups (early Lyme disease, STARI and healthy controls). For each scenario, two 
classification approaches were applied: random forest (RF) using the RandomForest package 
(61), with 16 features randomly selected for each clade and a total of 500 trees; and LASSO 
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logistic (two-way) and multinomial (three-way) regression analysis using the glmnet 
package (62), with the tuning parameter chosen for minimum misclassification error over a 
10-fold cross-validation. The ROC curve and AUC were generated for predicted responses 
on the Test-Set samples only using the pROC package (63). For the purpose of visualization, 
LASSO scores for individual patient samples were calculated by multiplying the respective 
regression coefficients (tables S4 and S6) resulting from LASSO analysis by the transformed 
abundance of each MF in the biosignature (38 MFs in the case of two-way classification and 
82 MFs in the case of three-way classification) and summing for each sample. The rgl 
package was used to generate the 3-dimensional scatterplot of LASSO scores (64).
Linear Discriminant Analysis—A linear discriminant analysis was performed with the 
82 MFs selected by the three-way LASSO model using linear discriminant analysis function 
in R. MF abundance data included in the linear discriminant analysis were from healthy 
controls from Colorado, Florida, and New York, and from STARI patients from North 
Carolina, Missouri, and other states. Before linear discriminant analysis data were 
transformed by taking the log2 value and standardizing to the mean 0 and variance 1 within 
each MF. Samples were differentiated by healthy and STARI.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Metabolic profiling for the identification and application of differentiating molecular 
features (MFs)
(A) LC-MS data from an initial Discovery-Set of early Lyme disease (EL) and STARI 
samples was used to identify a list of MFs that were targeted in a second LC-MS run. The 
data from both LC-MS runs was combined to form the Targeted-Discovery-Set. The MFs 
were then screened for consistency and robustness and this resulted in a final early Lyme 
disease-STARI biosignature of 261 MFs. This biosignature was used for downstream 
pathway analysis and for classification modeling. (B) Two training-data sets along with the 
261 MF biosignature list were used to train multiple classification models, random forest 
(RF) and least absolute shrinkage and selection operator (LASSO). Data from samples of 
twoTest-Sets (not included for the Discovery/Training-Set data) were blindly tested against 
the two-way (EL vs STARI) and three-way [EL vs STARI vs healthy controls (HC)] 
classification models. The regression coeficients used for each MF in the LASSO two-way 
and three-way classification models are provided in table S4 and S6, resepectively.
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Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI
The 122 presumptively identified MFs were analyzed using MetaboAnalyst to identify 
perturbed pathways between early Lyme disease and STARI. The color and size of each 
circle is based on P values and pathway impact values. Pathways with a > 0.1 impact were 
considered to be perturbed and differentially regulated between patients with early Lyme 
disease and STARI. A total of four pathways were affected: 1) glycerophospholipid 
metabolism; 2) sphingolipid metabolism; 3) valine, leucine and isoleucine biosynthesis; and 
4) phenylalanine metabolism.
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Fig. 3. Metabolite identification and association with NAE and PFAM metabolism
Structural identification of palmitoyl ethanolamide (A and B) and other NAEs (fig S1–S3) 
in the 261 MF biosignature indicated alteration of NAE metabolism (C), a pathway that can 
influence the production of PFAMs. Further MF identification revealed that palmitamide (D 
and E) and other PFAMs (fig S5 and S6) also differed in abundance between STARI and 
early Lyme disease patients. Structural identification was achieved by retention-time 
alignment (A and D) of authentic standard (top panel), authentic standard spiked in pooled 
patient sera (middle panel), and the targeted metabolite in pooled patient sera (bottom 
panel), and by comparison of MS/MS spectra (B and E) of the authentic standards (top) and 
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the targeted metabolites in patient sera (bottom). Retention-time alignments for palmitoyl 
ethanolamide (A) and palmitamide (D) were generated with extracted ion chromatograms 
for m/z 300.2892 and m/z 256.2632, respectively. The relationship of PFAM formation to 
NAE metabolism is highlighted in light green in diagram C. PLA, phospholipase A; PLC, 
phospholipase C; PLD, phospholipase D; ADH, alcohol dehydrogenase; PAM, 
peptidylglycine α-amidating monooxygenase.
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Fig. 4. Comparison of MF abundances from the Lyme disease-STARI biosignature against 
healthy controls
(A) Fourteen of the metabolites with level 1 or level 2 structural identifications were 
evaluated for abundance differences between early Lyme disease (green squares) and STARI 
(blue triangles) normalized to the metabolite abundance in healthy controls. Included are 
metabolites identified for NAE and PFAM metabolism. GP-NAE: glycerophospho-N-
palmitoyl ethanolamine; Lyso PA (20:4): arachidonoyl lysophosphatidic acid; CMPF: 3-
carboxy-4-methyl-5-propyl-2-furanpropanoic acid. The relative mean abundance and 95% 
confidence intervals are shown for each metabolite. (B) Abundance fold change ranges (x-
axis) plotted against the percent of MFs from the 261 MF early Lyme disease-STARI 
biosignature that have increased (dark blue) or decreased (light blue) abundances in STARI 
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relative to healthy controls, and increased (dark green) or decreased (light green) abundances 
in early Lyme disease relative to healthy controls. (C) The percentage of identical MFs in 
STARI and early Lyme disease that had the same directional and similar abundance fold 
change difference relative to healthy controls (y-axis). MFs were grouped based on 
abundance fold change ranges:1.0–1.4, 1.5–1.9, 2.0–2.4, 2.5–2.9, 3.0–3.4, and ≥3.5 (x-axis). 
MFs with increased fold changes relative to healthy controls are indicated in dark purple or 
and those with a decreased fold changes are indicated in light purple.
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Fig. 5. Evaluation of classification models’ performance
(A) LASSO scores (Xβ; i.e. the linear portion of the regression model) were calculated for 
Test-Set data of early Lyme disease (green dots) and STARI (blue triangles) serum samples 
by multiplying the transformed abundances of the 38 MFs identified in the two-way LASSO 
model by the LASSO coefficients of the model and summing for each sample. Scores are 
plotted along the y-axis; serum samples are plotted randomly along the x-axis for easier 
viewing. (B) An ROC curve demonstrates the level of discrimination that is achieved 
between early Lyme disease and STARI using the 38 MFs of the two-way LASSO 
classification model by depicting a true positive rate (sensitivity; early Lyme disease) versus 
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a false positive rate (specificity; STARI) for the Test-Set samples (table S6). The AUC was 
calculated to be 0.986. The diagonal line represents an AUC value of 0.5. The performance 
of two-tiered testing (red dot) on the same sample set (Test-Set 1) was included as a 
reference for the sensitivity and specificity of the current clinical laboratory test for Lyme 
disease. (C) LASSO scores (Xβi) were calculated for the Test-Set data of early Lyme 
disease (green spheres), STARI (blue spheres), and healthy control (black spheres) serum 
samples by multiplying the transformed abundances of the 82 MFs identified in the three-
way LASSO model by each of three LASSO coefficients used in the model. Each axis 
represents the sample score in the direction of one of the three sample groups. Scores are 
used in calculation of probabilities of class membership, with highest probability 
determining the predicted class. Although there is overlap, the three groups predominantly 
occupy distinct areas of the plot.
Molins et al. Page 26
Sci Transl Med. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 6. Evaluation of intra-and inter-group variability
Linear discriminant analysis was performed using the 82 MFs picked by LASSO in the 
three-way classification model to assess the intra-group variability based on the geographical 
region or laboratory from which STARI (CO-blue, solid; FL-green, dotted; and NY-red, 
dashed) and healthy control (MO-dark blue, solid; NC-light blue, dotted; and Other-green, 
dashed) sera were obtained. Only slight intra-group variation was observed. This analysis 
also compared and showed clear differentiation of all healthy control from STARI samples 
regardless of geographical region or laboratory origin. Healthy controls from FL were 
included in this analysis to demonstrate that healthy controls from an area with low 
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incidence of Lyme disease and where STARI cases occur do not differ from the healthy 
controls obtained from other regions and used in the classification modeling.
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